Attenuated Sex Steroid Receptor Expression in Fallopian Tube of Women with Ectopic Pregnancy

Horne, Andrew W; King, Anne E.; Shaw, Edward B.; McDonald, Sarah E.; Williams, Alistair; Saunders, Philippa T. K.; Critchley, Hilary O. D.

doi:10.1210/jc.2009-1476

Cited by 62 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of ARs has been documented throughout the female reproductive system including the ovary (Saunders et al 2000), fallopian tube (Horne et al 2009) and endometrium (Marshall et al 2011) consistent with a role for local or peripheral androgens in modulating the function of these tissues.…”

Section: Expression Of Ars In the Non-malignant Endometrium And Ovarymentioning

confidence: 86%

“…A mouse model using a conditional double KO of Dicer (Dicer1) and Pten demonstrated that high-grade serous cancers develop in the fallopian tube and metastasise to the ovary (Kim et al 2012). Although there is still evidence to support OSE cells as the originating cell type for some ovarian cancers (Auersperg 2013), the fact that both OSE cells and cells within the fallopian tube epithelium express AR (Edmondson et al 2002, Horne et al 2009, Mendez et al 2013 highlights the potential for androgens to modulate disease development and progression. Stem-like epithelial cells from the distal end of the fallopian tube capable of clonal growth and self-renewal have also been identified which may play a role in the initiation of serous tumours, although the impact of androgens on this cell population has not been investigated (Paik et al 2012).…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Evidence of androgen action in endometrial and ovarian cancers

Gibson

Simitsidellis

Collins

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Endometrial cancer (EC) and ovarian cancer are common gynaecological malignancies. The impact of androgen action in these cancers is poorly understood; however, there is emerging evidence to suggest that targeting androgen signalling may be of therapeutic benefit. Epidemiological evidence suggests that there is an increased risk of EC associated with exposure to elevated levels of androgens, and genetic variants in genes related to both androgen biosynthesis and action are associated with an increased risk of both EC and ovarian cancer. Androgen receptors (ARs) may be a potential therapeutic target in EC due to reported anti-proliferative activities of androgens. By contrast, androgens may promote growth of some ovarian cancers and anti-androgen therapy has been proposed. Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. This review considers the evidence that androgens may be important in the aetiology of EC and ovarian cancer with discussion of evidence for androgen action in normal and malignant endometrial and ovarian tissue.

show abstract

Section: Expression Of Ars In the Non-malignant Endometrium And Ovarymentioning

confidence: 86%

Section: Future Perspectivesmentioning

confidence: 99%

Evidence of androgen action in endometrial and ovarian cancers

Gibson

Simitsidellis

Collins

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Notably, endothelial and immune cells within the human endometrium are immunopositive for ERb but do not contain ERa protein (Henderson et al 2003, Greaves et al 2013. In the human fallopian tube, ER mRNAs are constitutively expressed during the menstrual cycle and have been immunolocalised to epithelial, stromal and smooth muscle cells (Horne et al 2009). In the cervix, expression of ERa and ERb has been documented in both stromal and epithelial cells (Taylor & Al-Azzawi 2000), whereas endothelial cells and leukocytes appear to express ERb alone as is the case in the endometrium (Stygar et al 2001).…”

Section: Figurementioning

confidence: 99%

Endocrine disruption of oestrogen action and female reproductive tract cancers

Gibson

Saunders

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Endocrine disrupting chemicals (EDC) are ubiquitous and persistent compounds that have the capacity to interfere with normal endocrine homoeostasis. The female reproductive tract is exquisitely sensitive to the action of sex steroids, and oestrogens play a key role in normal reproductive function. Malignancies of the female reproductive tract are the fourth most common cancer in women, with endometrial cancer accounting for most cases. Established risk factors for development of endometrial cancer include high BMI and exposure to oestrogens or synthetic compounds such as tamoxifen. Studies on cell and animal models have provided evidence that many EDC can bind oestrogen receptors and highlighted early life exposure as a window of risk for adverse lifelong effects on the reproductive system. The most robust evidence for a link between early life exposure to EDC and adverse reproductive health has come from studies on women who were exposed in utero to diethylstilbestrol. Demonstration that EDC can alter expression of members of the HOX gene cluster highlights one pathway that might be vulnerable to their actions. In summary, evidence for a direct link between EDC exposure and cancers of the reproductive system is currently incomplete. It will be challenging to attribute causality to any single EDC when exposure and development of malignancy may be separated by many years and influenced by lifestyle factors such as diet (a source of phytoestrogens) and adiposity. This review considers some of the evidence collected to date.

show abstract

“…Therefore, both estradiol and PG (progesterone) are necessary for LHinduced relaxation of porcine oviduct (1). The female reproductive system is exposed to fluctuating levels of sex steroids (oestrogen and progesterone), during the normal menstrual cycle (42). The expression of sex steroid hormone receptors (SHR) has yet to be comprehensively studied in the normal human Fallopian tube or in the context of tubal pathologies, such as ectopic pregnancy.…”

Section: Introductionmentioning

confidence: 99%

“…The expression of sex steroid hormone receptors (SHR) has yet to be comprehensively studied in the normal human Fallopian tube or in the context of tubal pathologies, such as ectopic pregnancy. Sex steroid-regulated Fallopian tube gene expression and function likely contribute to successful embryo tubal transport and implantation (42)(43).…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expressions of Receptors for Luteinizing Hormone/Human Chorionic Gonadotropic Hormone and for Sex Steroid Hormones in Pregnant Fallopian Tubes

Kaygusuz¹

2014

Acta Endo (Buc)

View full text Add to dashboard Cite

Background.There is no immunohistochemical study to show luteinizing hormone receptor (LHR), estrogen receptor (ER) and progesterone receptor (PR) in the pregnant Fallopian tubes (FT).Objective. To study LHR, ER, PR expression in FT containing an ectopic pregnancy (EP) and during the menstrual phase.Design. Thirty FT were obtained from women diagnosed with EP and twenty FT collected by hysterectomy performed for benign diseases not affecting the tubes were included in this study. Assessment of immunohistochemical expression staining LHR, ER, PR in epithelium, smooth muscle cell and blood vessel endothelium in FT containing an EP and during the different phases of menstrual cycle.Results. In ectopic pregnancy group we found LHR expression in epithelium in 30 cases, muscle cell in 28 cases, and endothelium in 9 cases in FT. In menstrual cycle group we noted LHR expression in FT in epithelium in all cases, muscle cell in 4 cases.Conclusion. There is a significant difference in the proportions of the existence of LH receptor immunostaining in the muscle cells for ectopic pregnancy group as compared to the menstrual cycle groups (p < 0.001). Our findings may suggest that the women who have increased LH receptors on muscle cells in Fallopian tubes are at increased risk for having external pregnancy.

show abstract

Attenuated Sex Steroid Receptor Expression in Fallopian Tube of Women with Ectopic Pregnancy

Cited by 62 publications

References 43 publications

Evidence of androgen action in endometrial and ovarian cancers

Evidence of androgen action in endometrial and ovarian cancers

Endocrine disruption of oestrogen action and female reproductive tract cancers

Immunohistochemical Expressions of Receptors for Luteinizing Hormone/Human Chorionic Gonadotropic Hormone and for Sex Steroid Hormones in Pregnant Fallopian Tubes

Contact Info

Product

Resources

About